| abstract |
The invention relates to a pharmaceutical dosage form which provides sustained release of tapentadol, wherein tapentadol is present in the form of a salt with phosphoric acid (orthophosphoric acid), preferably as dihydrogen phosphate salt. The dosage form of the invention provides improved sustained release properties, is particularly resistant to ethanol-induced dose dumping, and imparts, in addition to such resistance, additional safety properties associated with concomitant use of ethanol, e.g. alcoholic beverages. |